Published on 22/12/2025
Navigating Regulatory Challenges and Unlocking Opportunities for Phase 1 Trials in India
Introduction
Phase 1 clinical trials—often referred to as first-in-human (FIH) or early-phase trials—are critical for evaluating the safety, tolerability, and pharmacokinetics of new drugs. While India has emerged as a major hub for global clinical development, its contribution to Phase 1 trials has been relatively limited due to regulatory restrictions, infrastructure limitations, and ethical concerns. However, recent reforms under the New Drugs and Clinical Trials Rules (NDCTR), 2019 are gradually reshaping the landscape, making India more favorable for early-phase research.
This article explores the current status of Phase 1 trials in India, outlines key regulatory hurdles, and identifies emerging opportunities for sponsors, CROs, and academic researchers considering early-phase development in the country.
Background / Regulatory Framework
The regulatory approval and conduct of Phase 1 trials in India are governed by the Central Drugs Standard Control Organization (CDSCO) and outlined in the NDCTR 2019. Historically, India restricted Phase 1 trials of foreign molecules due to safety and ethical concerns. However, these limitations have been relaxed in recent years, particularly for drugs intended for life-threatening or rare diseases.
Regulatory Provisions Under NDCTR
- Rule 21(b): Prohibits first-in-human studies
Core Clinical Trial Insights
1. Current Status of Phase 1 Trials in India
- India permits Phase 1 trials of Indian-developed molecules with adequate preclinical data
- Foreign molecules can be tested under specific exemptions with CDSCO approval
- Most Phase 1 activity is concentrated in bioequivalence and biosimilar studies
- True FIH studies remain rare, limiting India’s full integration into global early development programs
2. Key Barriers to Phase 1 Trial Expansion
Regulatory Constraints
Despite relaxations, approvals for FIH trials of foreign molecules still undergo intensive scrutiny by Subject Expert Committees (SECs). CDSCO evaluates:
- Whether the drug has been tested in humans elsewhere
- Risk-benefit justification for Indian population
- Preclinical toxicology package compliance with OECD GLP
Limited Number of Accredited Sites
India has very few purpose-built Phase 1 units with clinical pharmacology capabilities, continuous monitoring, and intensive care facilities.
- Most sites cater to BA/BE studies, not complex FIH protocols
- GCP, ACLS-trained staff, and pharmacokinetics expertise are essential but scarce
Ethical and Public Perception Challenges
Media reports and public debates over subject safety have led to heightened scrutiny of early-phase studies. ECs are often risk-averse, leading to delays or rejections.
Insurance and Compensation Burdens
NDCTR mandates stringent compensation mechanisms for injury or death. High-risk Phase 1 trials lead to expensive insurance premiums and extensive sponsor liability.
3. Emerging Opportunities and Enablers
Indian Biotech and Startup Ecosystem
India’s biotech startups and academic R&D centers are developing novel compounds (especially in oncology, infectious diseases, and biologics). These entities are now seeking local Phase 1 execution capabilities to reduce dependence on overseas CROs.
Regulatory Flexibilities
CDSCO now allows FIH trials in India for foreign drugs under the following conditions:
- Orphan or rare disease indication
- Serious/life-threatening diseases with no alternatives
- Prior FIH data available from another country
- Innovator has an Indian affiliate or partner
These criteria have helped several biotech and repurposing trials initiate Phase 1 work in India in recent years.
Public-Private Partnerships
Institutes like AIIMS, NIMHANS, and PGI are collaborating with sponsors to create hybrid Phase 1 units inside academic settings, blending medical care with trial execution.
Training and Accreditation Initiatives
ICMR, CDSCO, and clinical trial networks have launched training programs for Phase 1 protocol design, risk assessment, and monitoring. Accreditation models for high-risk study sites are being developed.
Best Practices & Preventive Measures
- Use an experienced regulatory consultant to frame FIH justification
- Engage with CDSCO in pre-submission (Type B) meetings
- Select sites with 24×7 medical oversight and ICU access
- Train all staff in emergency response and GCP for early-phase trials
- Prepare robust safety monitoring plans and DSMB frameworks
Scientific & Regulatory Evidence
- NDCTR 2019 – Rule 21(b): Governs Phase 1 trials and exceptions for foreign drugs
- ICMR Guidelines (2017): Ethical oversight and risk-based review for high-risk protocols
- OECD GLP Compliance: Mandatory for preclinical toxicology data submission
- WHO GCP & ICH E6(R2): Required standards for Phase 1 study conduct
Special Considerations
Vulnerable Populations: Phase 1 trials in healthy volunteers must avoid coercion and must follow enhanced informed consent processes, including AV recording and LAR involvement (if applicable).
Compensation Complexity: For early-phase trials, sponsors must be prepared for significant financial exposure due to adverse event liability and medical care coverage.
Global Submission Compatibility: Sponsors conducting Phase 1 studies in India should ensure alignment with US FDA IND requirements and EMA Phase 1 guidance to maintain global acceptability of data.
When Sponsors Should Seek Regulatory Advice
- Planning a first-in-human study of a foreign molecule
- Conducting a dose-escalation study with limited Indian precedent
- Collaborating with an academic unit or startup for early-phase research
- Designing a Phase 1 study with complex endpoints or biomarkers
Engaging CDSCO through a formal Type B (scientific advice) meeting is highly recommended to clarify eligibility, dossier requirements, and justification frameworks before submitting Form CT-04.
FAQs
1. Are Phase 1 trials for foreign drugs allowed in India?
Yes, but only under specific conditions such as orphan designation, serious diseases, or with supporting FIH data from other countries.
2. What is the typical approval timeline for Phase 1 trials?
Up to 90 working days under NDCTR, but it can be shorter with complete documentation and prior regulatory engagement.
3. Are there dedicated Phase 1 units in India?
Yes, but very few. Most are attached to major hospitals or CROs with limited capacity. Expansion is ongoing.
4. Is informed consent mandatory for healthy volunteers?
Yes, with AV recording and robust documentation per NDCTR and ICMR guidelines.
5. How can a startup conduct Phase 1 trials in India?
They must collaborate with a CDSCO-approved site, obtain EC and regulatory approvals, and provide preclinical safety data compliant with OECD GLP.
Conclusion
While India has historically lagged in early-phase trials, evolving regulatory frameworks, growing domestic innovation, and infrastructure investments are beginning to change the narrative. Phase 1 trials in India now offer a viable option for startups, academic centers, and global sponsors seeking diverse populations and cost-effective execution. Regulatory diligence, site selection, and proactive planning remain the keys to success in this high-stakes area of clinical research.